{"id":"NCT00910247","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Eslicarbazepine Acetate Monotherapy Long Term Study","officialTitle":"Long Term Eslicarbazepine Acetate Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2017-04-15","completion":"2017-04-15","firstPosted":"2009-05-29","resultsPosted":"2018-07-17","lastUpdate":"2018-07-17"},"enrollment":274,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Eslicarbazepine acetate","otherNames":["SEP-0002093","BIA 2-093"]}],"arms":[{"label":"eslicarbazepine acetate","type":"EXPERIMENTAL"}],"summary":"This is a long term, open-label, safety extension study in subjects with partial onset seizures.","primaryOutcome":{"measure":"Number and Percent of Subjects With Treatment Emergent Adverse Events","timeFrame":"One year","effectByArm":[{"arm":"Eslicarbazepine Acetate","deltaMin":220,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":5},"locations":{"siteCount":122,"countries":["United States","Bulgaria","Canada","Czechia","Serbia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":274},"commonTop":["headache","dizziness","nausea","nasopharyngitis","fatigue"]}}